Cite
HARVARD Citation
Sloan, A. et al. (n.d.). 141 Phase I Trial of Genetically Modified Hematopoietic Progenitor Cells Facilitate Bone Marrow Chemoprotection and Enabling TMZ/O6BG Dose Escalation Resulting in Improved Survival. Clinical neurosurgery. p. . [Online].